Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
CPT Pharmacometrics Syst Pharmacol ; 5(3): 93-122, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27069774

RESUMEN

This document was developed to enable greater consistency in the practice, application, and documentation of Model-Informed Drug Discovery and Development (MID3) across the pharmaceutical industry. A collection of "good practice" recommendations are assembled here in order to minimize the heterogeneity in both the quality and content of MID3 implementation and documentation. The three major objectives of this white paper are to: i) inform company decision makers how the strategic integration of MID3 can benefit R&D efficiency; ii) provide MID3 analysts with sufficient material to enhance the planning, rigor, and consistency of the application of MID3; and iii) provide regulatory authorities with substrate to develop MID3 related and/or MID3 enabled guidelines.


Asunto(s)
Guías como Asunto , Tecnología Farmacéutica/normas , Documentación , Diseño de Fármacos , Tecnología Farmacéutica/métodos
2.
Ren Fail ; 12(3): 171-6, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2287769

RESUMEN

The protective effect of the platelet-activating factor (PAF) antagonist, BN 52021, was assessed on cis-diammine-dichloroplatinum (CDDP)-induced nephrotoxicity. Wistar male rats were treated with either a single dose of CDDP (10 mg/kg b.w. ip) alone or in association with 7 daily doses of BN 52021 (10 mg/kg b.w. ip). At the end of the experiment, the CDDP-treated rats lost 25% of body weight and serum creatinine and urea increased from 0.041 +/- 0.006 mmol/l and 0.165 +/- 0.007 g/l for the control group to 0.202 +/- 0.019 mmol/l and 1.51 +/- 0.131 g/l versus CDDP respectively. Body weight, serum creatinine, serum urea and creatinine clearances were similar to the control group in animals treated with CDDP and BN 52021. CDDP caused proximal tubular necrosis and dilatation of cortical collecting tubes, changes that were markedly less in the BN 52021-protected animals. The concomitant administration of BN 52021 with CDDP did not modify the plasma pharmacokinetic of CDDP. In addition, BN 52021 did not interfere with the antiproliferative and antitumoral actions of CDDP in cultured human tumor cells. BN 52021 therefore could prevent the nephrotoxicity of CDDP.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Cisplatino/antagonistas & inhibidores , Diterpenos , Lactonas/farmacología , Factor de Activación Plaquetaria/antagonistas & inhibidores , Lesión Renal Aguda/fisiopatología , Animales , Nitrógeno de la Urea Sanguínea , Peso Corporal/efectos de los fármacos , Cisplatino/farmacocinética , Cisplatino/toxicidad , Creatinina/metabolismo , Ginkgólidos , Tasa de Filtración Glomerular/efectos de los fármacos , Masculino , Ratas , Ratas Endogámicas , Circulación Renal/efectos de los fármacos , Células Tumorales Cultivadas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA